跳至主要内容
临床试验/ACTRN12606000447550
ACTRN12606000447550尚未招募不适用

A Double-Blind, Active-Controlled, Long-Term Safety Extension Study of Optimized Doses of Darusentan in Subjects with Resistant Hypertension Despite Receiving Combination Therapy with Three or More Antihypertensive Drugs, Including a Diuretic, as Compared to Guanfacine (Protocol DAR-312-E)

Myogen, Inc.0 个研究点目标入组 700 人开始时间: 2006年10月18日最近更新:
适应症

试验速览

阶段
不适用
状态
尚未招募
发起方
Myogen, Inc.
入组人数
700

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Treatment
盲法
Blinded (masking used)

入排标准

年龄范围
35 Years 至 80 Years(—)
性别
All

入选标准

  • 1) Subjects must be competent to provide written informed consent; 2) Subjects must have completed participation in the DAR-312; 3) Female subjects must be of non-childbearing potential (post menopausal for at least 2 years or surgically sterile).

排除标准

  • 1) Subjects who discontinue treatment with study drug prior to the end of the Maintenance Period in DAR-312 due to a study drug-related adverse event (AE); 2) Subjects who experience a study drug-related serious adverse event (SAE) during the DAR-312 study.

研究者

发起方
Myogen, Inc.

相似试验